Document is current
Any future updates will be listed below
-
Authors
Assoumou, Lambert https://orcid.org/0000-0002-5547-1796
Baldé, Raghiatou
Katlama, Christine
Abbar, Baptiste
Delobel, Pierre
Allegre, Thierry
Lavole, Armelle
Makinson, Alain
Zaegel-Faucher, Olivia
Greillier, Laurent
Soulie, Cathia
Veyri, Marianne
Bertheau, Mathilde
Algarte Genin, Michèle
Gibowski, Séverine
Marcelin, Anne-Geneviève
Bihan, Kevin
Baron, Marine
Costagliola, Dominique
Lambotte, Olivier
Spano, Jean-Philippe
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03354936 at ClinicalTrials.govnct03354936 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study
https://doi.org/10.1136/jitc-2024-009728
nct03354936 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study
https://doi.org/10.1136/jitc-2024-009728
Documents that mention this clinical trial
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study
https://doi.org/10.1136/jitc-2024-009728
-
Funding
Funding for this research was provided by:
ANRS/MIE Maladies Infectieuses Emergentes (N/A)
- License Information
